Rabey J, Vardi J, Glaubman H, Streifler M
Eur Neurol. 1978;17(6):345-50. doi: 10.1159/000114973.
Nocturnal sleep patterns were registered from 6 parkinsonian patients treated with bromocryptine, ("-Br-L-ergocryptine, C.B.-154) a dopamine-like agonist. No significant differences in their sleep patterns were found in comparison with patients treated with L-dopa. Since bromocryptine acts direct on the dopaminergic receptor sites, it is suggested that the disturbed EEG sleep patterns in parkinsonian patients cannot be explained by altered dopaminergic or serotoninergic effects whether pre- or postsynaptic.
对6名接受溴隐亭（“-溴-L-麦角隐亭，C.B.-154）治疗的帕金森病患者的夜间睡眠模式进行了记录，溴隐亭是一种多巴胺样激动剂。与接受左旋多巴治疗的患者相比，未发现他们的睡眠模式有显著差异。由于溴隐亭直接作用于多巴胺能受体位点，因此有人提出，帕金森病患者脑电图睡眠模式紊乱不能用多巴胺能或5-羟色胺能效应的改变来解释，无论是突触前还是突触后的改变。
